Teva announces settlement with lupin resolving austedo® (deutetrabenazine) patent dispute

Tel aviv, israel & parsippany, n.j.--(business wire)--teva branded pharmaceutical products r&d, inc. and auspex pharmaceuticals, inc., u.s. affiliates of teva pharmaceutical industries ltd. (nyse and tase: teva), have reached an agreement with lupin to resolve the dispute over lupin's abbreviated new drug application (“anda") for a generic deutetrabenazine product. teva and lupin have been involved in a patent infringement litigation in which teva asserted a number of patents against lupin
TEVA Ratings Summary
TEVA Quant Ranking